Clinical Trial: Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07646639) titled 'Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC' on Sept. 15, 2025.

Brief Summary: This prospective, randomized phase II trial is designed to evaluate whether low-dose short-course radiotherapy differs from common-dose short-course radiotherapy in terms of efficacy when both regimens are sequentially combined with CAPOX, a PD-1 monoclonal antibody, and interleukin-2 (IL-2) in patients with locally advanced rectal cancer. The study is based on findings from our previous single-center, single-arm PRIDE01 study, in which neoadjuvant short-course radiotherapy followed by systemic chemoimmunotherapy and IL-2 demonstrated e...